Institutional investors purchased a net $1.8 million shares of PBYI during the quarter ended June 2017. This may signal that the smart money is gaining interest in this company as the 97.50% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
T. ROWE PRICE ASSOCIATES, INC. Bought 1.5 Million shares of Puma Biotechnology Inc